Abstract
No public abstract is available from the verified source records.
Weifan Yin, Qiuming Zeng, Guanzhong Shi, Yuzhen Ouyang, Zeyi Wen, Haobing Cai, Liu Wang, Huan Yang
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
No local reference links have been materialized yet.
No local citing links have been materialized yet.
MuSK antibodies, lessons learned from poly- and monoclonality
10.1016/j.jaut.2020.102488 · 2020
Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease
10.3389/fimmu.2023.1212757 · 2023
Rituximab treatment of myasthenia gravis: a systematic review
10.1002/mus.25597 · 2017
Efficacy and safety of low-dose rituximab in the treatment of myasthenia gravis: a systemic review and meta-analysis
10.3389/fneur.2024.1439899 · 2024
Efficacy and safety of rituximab in anti-MuSK myasthenia Gravis: a systematic review and meta-analysis
10.1038/s41598-025-90937-w · 2025
Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review
10.1212/wnl.0000000000004341 · 2017
Opportunities and limitations of B cell depletion approaches in SLE
10.1038/s41584-024-01210-9 · 2025
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
10.1177/13524585221079731 · 2022
Therapeutic effect of ofatumumab in patients with myasthenia gravis: immunoregulation of follicular T helper cells and T helper type 17 cells
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.3389/fneur.2023.1278250 · 2023
Normalized circulating Tfh and Th17 associates with improvement in myasthenia gravis treated with ofatumumab
2024
Differential response to ofatumumab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study
2026
Chinese guideline for diagnosis and treatment of myasthenia gravis (2025 edition)
2025
Utilization of MG-ADL in myasthenia gravis clinical research and care
10.1002/mus.27476 · 2022
Minimal clinically important difference in myasthenia gravis: outcomes from a randomized trial
10.1002/mus.23988 · 2014
Performance of individual items of the quantitative myasthenia gravis score
10.1016/j.nmd.2013.02.008 · 2013
Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis
10.1016/j.msard.2021.102787 · 2021
Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability
10.1007/s40265-024-02011-w · 2024
Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics
10.1093/rheumatology/ker417 · 2012
Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody
10.1002/mus.27233 · 2021
The burden of recurrent respiratory tract infections in adult population: a population-based study in primary care
10.1093/fampra/cmae009 · 2024
Efficacy and safety of low-dose rituximab in MuSK antibody-positive myasthenia gravis: a single-center retrospective study
2026
The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis
10.1002/acn3.564 · 2018
Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis
10.1001/jamaneurol.2016.4190 · 2017
Efficacy and safety of low-dose rituximab in Anti-MuSK myasthenia gravis patients: a retrospective study
10.2147/ndt.s358851 · 2022
Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study
10.1007/s00415-019-09296-y · 2019
Rituximab in refractory myasthenia gravis: extended prospective study results
10.1002/mus.26156 · 2018
Long-lasting treatment effect of rituximab in MuSK myasthenia
10.1212/wnl.0b013e3182407982 · 2012
Repeated low-dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis
10.1177/1756286419871187 · 2019
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
10.4161/mabs.22771 · 2013
Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies
10.1016/j.ekir.2024.12.012 · 2025
Human or chimeric monoclonal Anti-CD20 antibodies for children with nephrotic syndrome: a superiority randomized trial
10.1681/asn.2021040561 · 2021
Regulation of B lymphocyte activation by complement C3 and the B cell coreceptor complex
10.1016/j.coi.2005.03.001 · 2005
Emerging role of the spleen in the pharmacokinetics of monoclonal antibodies, nanoparticles and exosomes
10.3390/ijms18061249 · 2017
Retrospective analysis of safety and outcomes of rituximab for myasthenia gravis in patients >/=65 years old
10.1002/mus.27393 · 2021
High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria
10.1007/s00415-019-09191-6 · 2019
Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab
10.1080/08830185.2017.1346092 · 2017
Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab
10.1016/j.anai.2023.01.018 · 2023
Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study
10.1007/s00296-021-04847-x · 2021
No additional external references are available.